8E8 Stock Chart & Stats
€0.47
€0.03(20.86%)
At close: 4:00 PM EST
€0.47
€0.03(20.86%)
Day’s Range― - ―
52-Week Range€0.18 - €0.67
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€14.30M
Enterprise Value€239.86
Total Cash (Recent Filing)€17.86M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding66,736,374
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)10.19
Price to Sales (P/S)0.00
P/FCF Ratio-11.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving no reported debt reduces refinancing and interest-rate vulnerability and preserves strategic optionality. This structural advantage lengthens runway flexibility for an early-stage biotech, lowering fixed financing costs and making capital raises less pressured by near-term interest obligations.
Next-generation Cell & Gene Therapy PipelineA pipeline centered on CAR T and enhanced cell therapies addresses persistent unmet needs in hematologic and solid tumors. Structural R&D focus on persistence and activity gives potential durable competitive differentiation and partnership appeal if clinical readouts show progress over the next several months.
Very High Gross Margin Profile When Revenue ExistsHigh gross margins indicate scalable unit economics once products or services reach commercial scale. For a biotech, strong gross margins support long-term profitability potential and allow incremental revenue to more effectively leverage fixed R&D and SG&A spend as commercialization progresses.
Bears Say
Sharp Revenue Decline And Low Revenue BaseA very small and rapidly shrinking revenue base signals weak commercial traction or one-off revenues. Structurally, low recurring sales reduce internal funding capacity, force reliance on external capital, and make sustaining R&D and development timelines difficult without successful product commercialization or partnership deals.
Large And Persistent Cash BurnOperating and free cash flow deficits of roughly -27.8m TTM create an ongoing financing requirement. This persistent burn constrains runway, raises likelihood of dilutive capital raises or partnerships, and can delay development milestones if funding terms are unfavorable or market access to capital tightens.
Deep Losses And Negative Returns On EquitySustained, large negative margins and sharply negative ROE erode shareholder equity and highlight reliance on external funding. Structurally this limits strategic flexibility, increases dilution risk, and may impair ability to attract long-term partnerships or scale operations without clear evidence of clinical or commercial progress.
8E8 FAQ
What was Elicera Therapeutics AB’s price range in the past 12 months?
Elicera Therapeutics AB lowest stock price was €0.18 and its highest was €0.67 in the past 12 months.
What is Elicera Therapeutics AB’s market cap?
Elicera Therapeutics AB’s market cap is €14.30M.
When is Elicera Therapeutics AB’s upcoming earnings report date?
Elicera Therapeutics AB’s upcoming earnings report date is Aug 21, 2026 which is in 22 days.
How were Elicera Therapeutics AB’s earnings last quarter?
Elicera Therapeutics AB released its earnings results on Apr 21, 2026. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.009.
Is Elicera Therapeutics AB overvalued?
According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued.
Does Elicera Therapeutics AB pay dividends?
Elicera Therapeutics AB does not currently pay dividends.
What is Elicera Therapeutics AB’s EPS estimate?
Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elicera Therapeutics AB have?
Elicera Therapeutics AB has 66,736,374 shares outstanding.
What happened to Elicera Therapeutics AB’s price movement after its last earnings report?
Elicera Therapeutics AB reported an EPS of -€0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.677%.
Which hedge fund is a major shareholder of Elicera Therapeutics AB?
Currently, no hedge funds are holding shares in DE:8E8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Elicera Therapeutics AB
Elicera Therapeutics AB (publ), a Swedish immuno-oncology firm founded in Göteborg in 2014, is dedicated to the clinical development of cell and gene therapies that harness the immune system to combat cancer. Its promising pipeline features several drug candidates, including ELC-100, which is currently undergoing Phase I/II trials for neuroendocrine tumors. The company is also advancing ELC-201 and ELC-401 through preclinical development, with ELC-401 specifically targeting glioblastoma multiforme (a form of brain tumor). Furthermore, Elicera is developing ELC-301, a CAR T-cell therapy intended for the treatment of Non-Hodgkin's B-cell lymphoma. A cornerstone of their work is the iTANK technology platform, engineered to enhance the efficacy of their CAR T-cell therapies and stimulate killer T-cells to attack cancerous cells.
Technical Analysis
Isofol Medical AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
―
Bio-Works Technologies AB
―